The Role of Chimeric Antigen Receptor-T Cell Therapy in the Treatment of Hematological Malignancies: Advantages, Trials, and Tribulations, and the Road Ahead

Sai Rohit Reddy 1, Adiona Llukmani 1, Ayat Hashim 1, Dana R. Haddad 1, Dutt S. Patel 1, Farrukh Ahmad 1, Majdi Abu Sneineh 1, Domonick K. Gordon 1, 2

1. Internal Medicine, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA
2. Internal Medicine, Scarborough General Hospital, Scarborough, TTO

Corresponding author: Sai Rohit Reddy, rohitreddy6705.medico@gmail.com

Abstract

Immunotherapy is the upcoming trend in cancer treatment. Traditional cancer treatment methods include surgical resection, radiotherapy, chemotherapy, small molecule targeted drugs, monoclonal antibodies, and hematopoietic stem cell transplantation (HSCT). Surgical resection is useful for early-stage patients but not for metastatic cancer cells; radiotherapy and chemotherapy are more common but produce substantial damage to normal tissues and have poor selectivity. Targeted drugs, including monoclonal antibodies, have better comprehensive efficacy but can also encourage gene mutation of tumor cells and drug tolerance. HSCT is effective, but choosing a donor is often difficult, and the graft is also prone to rejection. Thus, chimeric antigen receptor (CAR)-T cell therapy, a form of cellular/adoptive immunotherapy, is at the forefront of cancer therapy treatments due to its sustained remission, fewer side effects, and a better quality of life. CAR-T cell therapy involves genetically modifying the T cells and multiplying their numbers to kill cancer cells. This review article gives an insight into how the CAR-T cells have evolved from simple T cells with modest immune function to genetically engineered robust counterparts that brought great hope in the treatment of hematological malignancies. Much research has been undertaken during the past decade to design and deliver CAR-T cells. This has led to successful outcomes in leukemias, lymphomas, and multiple myeloma, paving the way for expanding CAR therapy. Despite tremendous progress, CAR-T cell therapies are faced with many challenges. Areas for improvement include limited T cell persistence, tumor escape, immunosuppressive components in the tumor microenvironment, cancer relapse rate, manufacturing time, and production cost. In this manuscript, we summarize the innovations in the design and delivery of CAR technologies, their applications in hematological malignancies, limitations to its widespread application, latest developments, and the future scope of research to counter the challenges and improve its effectiveness and persistence.

Categories: Internal Medicine, Oncology, Hematology
Keywords: adoptive immunotherapy, hematological malignancies, side effects of car therapies, car-t cells in hematological malignancies, car-t cell design, next generation car-t cells, immunotherapy and hematological malignancies, car-t cell therapy, safety strategies in car therapy, fda approved car therapies

Introduction And Background

Immunotherapy is an upcoming trend in cancer treatment that aims to enhance the host immune system to recognize and destroy cancer cells. It includes monoclonal antibodies, immune checkpoint inhibitors, cancer vaccines, adoptive cell therapy, and cytokines. Adoptive immunotherapy is a type of immunotherapy that involves modifying the T cells, which act as “living drugs” that multiply in the patient’s body, recognize the cancer cells that possess the specific antigen, and kill them [1]. Chimeric antigen receptor (CAR)-T cell is not a drug used in chemotherapy; instead, it is a living biologic manufactured from the patient’s blood cells. This kind of cancer therapy leads to sustained remission, lesser side effects, and better quality of patients’ lives, making it the preferred treatment plan over the other conventional cancer treatments like chemotherapy, radiotherapy, and surgical excision [2].

T cells play a vital role in the cell-mediated immune response. During the past few years, many therapies have been developed to redirect, culture, and enhance T cells against tumors [3]. The T cell-based adoptive immunotherapy revolves around developing new means to deal with malignancies, especially hematologic cancers. This emerging therapy includes three models: tumor-infiltrating lymphocytes (TILs), T cell receptor (TCR)-modified T cells, and CAR-T cells [2]. As compared to CAR-T cell therapy, the first two techniques do not make a considerable modification of the T cells per se, so the efficacy is not substantial. Also, the process of production, the low success rate, and the dependence upon vaccination limit their development [2-5]. As an up-and-coming therapeutic regimen, CAR-T cells have stood the test of time for the last three decades, and many of its products have now been approved by the United States Food and Drug Administration (FDA) [6,7].
Advantages

The advantage of CAR-T cell therapy is the short treatment time required for completion. It scores over other traditional cancer treatments in long-term remission with a better quality of patient’s life. As compared to stem cell transplants, which also involve aggressive chemotherapy, most patients have a rapid recovery with CAR-T cell therapy [8]. Unlike TILs and TCRs, which are dependent on Major histocompatibility complex (MHC) expression of target cells for antigen recognition, CAR-T cells recognize the specific antigens, independent of antigen processing by the target cells and MHC restrictions, thus, in turn, killing tumor cells effectively [5,9,10].

Process of CAR-T cell therapy

The basic process of CAR-T cell therapy involves apheresis, followed by leukapheresis, where we withdraw blood from the patient’s body, and lymphocytes (white blood cells) are separated. It is then forwarded to the lab for genetic engineering, where genes are then inserted via the inactive virus/non-virus vector into T cells to produce chimeric antigen receptors (CARs) on their surface. These re-engineered CAR-T cells are multiplied in the lab for roughly two to three weeks, then frozen and sent for reinfusion [5,6,11,12]. Simultaneously, we administer conditioning chemotherapy to lower the WBC’s of the patient and set the stage for infusion of thawed CAR-T cells. The CAR-T cells then help to kill the tumor cells via granzyme/perforin-mediated apoptosis [12,13].

Design of CAR-T cells

CAR-T cells are composed of extracellular, transmembrane, and intracellular domains and a flexible hinge that also adds to target recognition efficiency [11]. The extracellular domain has an antigen-binding domain, i.e., single-chain variable fragment (scFv) that recognizes tumor-associated antigens. The intracellular domain consists of the immunoreceptor tyrosine-based activation motif (ITAM) of the TCR complex CD3ζ chain, which activates the costimulatory signal [3].

CAR technologies are being widely researched and developed into successive generations. The first-generation CARs contain a single-chain variable fragment (scFv), linkers, a transmembrane domain, and intracellular CD3ζITAMs [2,14,15]. The second-generation CARs have an additional intracelluar costimulatory domain, e.g., CD28 or the 4-1BB receptor (CD137). The third-generation CARs have two additional costimulatory domains, e.g., CD 28 or CD 4-1BB and CD 134. The fourth-generation CAR-T cells additionally consist of various costimulatory components such as cytokines, antibodies, or other functional proteins [14,15]. They can identify and remove some antigens that are not recognized by earlier generation T cells. A summary of different generations of modified and refined CAR-T cells has been enlisted below (Figure 1).

![The molecules of all generations of CAR T cells](image)

**FIGURE 1:** The different generations of CAR-T cells. (In addition to hematological malignancies, some fourth generation CAR T cells have also shown progress in the treatment of solid tumors, autoimmune...
Application of CAR technologies in the treatment of hematological malignancies

To date, CAR-T cell therapy has been tried and tested in a variety of hematological malignancies, including relapsed/refractory (r/r) mantle cell lymphoma, B cell non-Hodgkin lymphoma-B-NHL (primary mediastinal B cell lymphoma, diffuse large cell lymphoma, and follicular lymphoma), multiple myeloma (MM), chronic lymphoblastic lymphocytic leukemia (CLL), adult and pediatric relapsed/refractory acute lymphoblastic leukemia (ALL) [7,16,17]. The CD19-specific CAR-T cells in the B-ALL patients can achieve an average complete remission rate of 70-94% [2,18].

Professionals have been studying the CAR-T cell therapies with many permutations and combinations with failures/relapses, refractory treatments, and a few positive strides accomplished to date. Moreover, several of them were approved by FDA, including Kymriah from Novartis, which is being used mainly for children and young adults with ALL and also in diffuse large B cell lymphoma (DLBCL); Yescarta from Gilead, for use in DLBCL; and Kite’s Tecartus, accepted as the first CAR-T treatment for r/r mantle cell lymphoma [6,19-22].

Clinical trials revolving around hematological malignancies have shown that CAR-T cell therapy has helped bring remission in patients with multiple futile cancer treatments, which lasted for years [8]. Besides, it can also prevent their cancer from getting worse, helps them to live longer, and in a few cases, they can also benefit from treatments such as stem cell transplantation [14]. However, the limitation is the relapse, which may be mediated by antigen escape and the limited persistence of CAR-T cells [18].

Challenges in chimeric antigen receptor technologies

Despite the undeniable benefits of CAR therapies, there are still many side effects required to be kept under check with utmost scrutiny while administering it. Neurotoxicity and the cytokine release syndrome (CRS) are the commonly encountered side effects in most patients. Others include CAR-T cell-related encephalopathy syndrome, macrophage activation syndrome, hemophagocytic lymphohistiocytosis, graft-versus-host disease, on-target/off-tumor toxicity, anaphylaxis, and infections [3,8,23,24]. CRS occurs due to excess T cell proliferation and destruction of the cancer cells, causing an immune response in the body [3,16]. Neurotoxicity is a side effect in most patients with anti CD19 CAR-T cell therapy. Evidence of neurotoxicity includes endothelial dysfunction, vascular instability, capillary leak, blood-brain barrier disruption, and disseminated intravascular coagulation (DIC) [3,23,25]. As the same molecular biomarkers can be expressed in some normal tissues or organs, especially the lymphatic tissues, CAR-T cell therapy can destroy normal tissues referred to as on-target/off-tumor toxicity, e.g., B cell aplasia in anti-CD19/20 CAR-T cell treatment [3].

While there has been growing research in this area, the limited T cell persistence leading to relapse and adverse effects become bottlenecks to this approach’s widespread use. Through this traditional review article, we intend to provide an insight into the advantages and successful outcomes of CAR-T cell therapy, the barriers for widespread adoption, and the expected modalities of ongoing research aiming to prevent resistance and relapses by not only focusing on the manufacturing of CAR-T cells but also by studying the effects of surrounding cells, previous treatments, tumor microenvironment causing CAR-T cells exhaustion and other relevant issues.

Search strategy and study selection

During this review, we used PubMed and other electronic databases like Medline and PubMed Central to search for relevant publications. The keywords entered in the search process included "adoptive immunotherapy," "hematological malignancies," "immunotherapy and hematological malignancies," "CAR-T cell therapy," "next generation CAR-T cells," "approved CAR-T therapies," "side-effects of CAR therapies," "CAR-T cell design," "safety strategies in CAR therapy," and "CAR-T cells in hematological malignancies.” Articles were searched from January 2014 to November 2020 and later imported into Mendeley for organization and citations. After removing the duplicates, we reviewed all titles and abstracts using the inclusion and exclusion criteria. Figure 2 shows a summary of the study selection process in a Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram.
Study selection criteria

All articles in the last six years (from January 2014), (2) articles in only English language, (3) studies originating from any country, and (4) all studies about adoptive immune therapy and CAR-T cell therapy in humans were included. In contrast, all publications before 2014, articles not available in English and not pertaining to humans, gray literature, and articles not available in full text were excluded. It was followed by reviewing the abstract for relevance, and then finally analyzing the full-text to meet our review article’s goals.

Review

A novel breakthrough in cancer immunotherapy has been CAR-T cell therapy, with ongoing research spanning over 30 years. It activates the host’s immune defenses rather than directly kill the tumor cells. Traditional cancer therapies like radiotherapy and chemotherapy have short-term therapeutic effects, cause side effects, and decrease patients’ quality of life. In contrast, CAR-T cell therapy provides sustained remission and better quality-adjusted life years [2]. This therapy has been developing rapidly, with many globally established clinical trials with excellent commercial potential. The first study on this therapy was done by Gross et al. laying the groundwork for the first generation of CAR-T cells. There have also been advances in how long it takes to produce a batch of CAR-T cells as it initially took several weeks, but many labs have now reduced the time to less than seven days. We have summarized the process of manufacture and delivery of CAR-T cells to a patient in the diagram below (Figure 3).
CAR design and innovations in the development of CAR technologies

There has been much impressive research and development in CAR-T cell design and delivery to improve the efficiency, persistence, infiltration, and anti-apoptosis ability to treat tumor cells [3,14,15]. The basic structure of CAR-T cell has an extracellular domain consisting of a tumor-targeting/antigen-binding structure, i.e., an antibody derived single-chain variable fragment (scFVs); a hinge region; a transmembrane domain; and an intracellular signaling domain consisting of an activation motif with the CD3 zeta chain (T cell receptor complex), that provides signals for T cell activation leading to the production of toxic cytokines (e.g., IFN-γ, TNF-α) to attack tumor cells. Unlike typical T cell receptors, CARs are synthetic receptors binding to the target cells' surface antigens, independent of antigen processing by the target cells and independent of MHC restrictions, thus preventing the immune escape of tumor cells [11,13,15,26].

There are four generations of CAR-T cells, created via continuous modifications and improvement of the effects of intracellular signaling domains [3,14,15]. The first generation consists of an scFV antigen-binding epitope and a single CD3ζ intracellular domain. Their anti-tumor action was limited in vivo, with the decrease in T cell proliferation and cytokine secretion, ultimately leading to T cells' apoptosis. The second generation of CAR-T cells incorporated an additional costimulatory molecule, i.e., CD28 or the 4-1BB receptor (CD137), which increased CAR-T cell proliferation, cytokine secretion, and secretion of the anti-apoptotic proteins and also delayed the antigen-induced cell death. Third-generation CAR-T cells have two additional costimulatory molecules, i.e., 4-1BB and CD28, which helped them produce a significant amount of toxic cytokines (IFN-γ) compared to first-generation or second-generation CAR-T cells that enhance the lysis of tumor cells. However, recent studies report that only the second-generation CAR-T cells can activate CD3ζ and have more robust signal transduction and anti-tumor effects than the third-generation CAR-T cells. The fourth generation of CAR-T cells, also known as T cells redirected for universal cytokine killing (TRUCKs), contains an activated T cell nuclear factor transcriptional counterpart that helps them secrete specific cytokines (interleukin-12). These cytokines modify the tumor microenvironment (one of the significant causes of resistance to CAR-T cells of earlier generations) and reconstitute the immune system by recruiting and activating other immune cells to induce an immune response, creating a hostile environment for tumor survival [13,27].

However, further modification of CAR-T cells by adding additional CAR parts, to form the next-generation CAR-T cells, has led to an improvement in their effectiveness and persistence [15,28]. Reconstructing the CAR part is also a new approach to antigen escape or coexistence of multiple tumor antigens in lymphoma, multiple myeloma, and other types of malignancies.
Application of CAR-T cell therapies in hematological malignancies

Genetically modified autologous T cells with redirected specificity to tumor antigens may combine advantages of cellular therapy (amplified response), antibody therapy (specificity), and vaccine therapy (memory activity). Chimeric antigen receptor-T cell therapy has been emerging cancer immunotherapy that has shown remarkable results, especially in hematological malignancies. The extensive exploratory work in the application of these therapies has led to successful outcomes (Table 1) in treating malignancies in children and adults such as recurrent B cell acute lymphoblastic leukemia, chronic lymphocytic leukemia, lymphomas including non-Hodgkin’s lymphoma; t/r follicular lymphoma (FL); and diffuse large B cell lymphoma and multiple myeloma [3]. Clinical trials of CAR-T cell therapy mainly focused on CD19, CD20, CD22, CD30, CD38, BCMA, GPC3, and other famous antigen targets. In the United States, clinical trials targeting CD19 accounted for more than 40% of the CAR-T cell trials. Till August 2017, there were approximately 200 clinical trials involving CAR-T cells worldwide, and roughly about 65% of them involved hematological malignancies, of which 80% involved CD 19 CAR-T cells targeting B cell cancers [2].

Currently, CAR-T cell projects in clinical research involve more than 48 targets. As of June 2020, 357 clinical trials in China, 256 trials in the United States, and 58 trials in other countries have been registered [29].

| Trade name/generic name manufacturer | Reference | Drug type | Treatment | Target | FDA approval |
|-------------------------------------|-----------|-----------|-----------|--------|--------------|
| Kymriah (Tisagenlecleucel) - Novartis Pharmaceuticals Corporation | [20] | Immunotherapy | Pediatric and young adult patients with ALL and DLBCL | CD19 protein found on the surface of cancer cells | August 2017 |
| Yescarta (Axicabtagene ciloleucel) - Kite Pharma, Inc | [21] | Immunotherapy | Adults with DLBCL | CD19 protein found on the surface of cancer cells | October 2017 |
| Tecartus (Brexucabtageneautoleucel) - Kite Pharma, Inc (Gilead) | [22] | Immunotherapy | Relapsed or refractory MCL | CD19 protein found on the surface of cancer cells | July 2020 |
| Actemra (Tocilizumab) - Genentech, Inc | [30] | Anti-cytokine therapy (monoclonal antibodies) | Adults and pediatric patients of 2 years of age or older with CAR-T cell-induced CRS | Interleukin-6 (IL-6) receptor | August 2017 |

TABLE 1: FDA-approved CAR-T cell immunotherapies/treatments in hematological malignancies.

ALL: acute lymphoblastic leukemia; CAR: chimeric antigen receptor; CD: cluster of differentiation; CRS: cytokine release syndrome; DLBCL: diffuse large B-cell lymphoma; IL: interleukin; MCL: mantle cell lymphoma

Limitations in the widespread application of CAR-T cell therapies

Though there is much progress achieved, the usage of CAR-T cell therapy still involves many challenges.

Unfavorable Side-Effects

After CAR-T cell infusion, patients may encounter some severe side effects such as CRS and neurological toxicities, as the cells multiply in the body to fight cancer [3,6,25,31]. The extent of these side-effects (Table 2) and efficacy of CAR treatment depends upon the treatments that the patient has undergone previously, the amount of lymphodepletion, chemotherapy regimen, and the extent of disease at the time of infusion [28,32,33].

| Side-effect | Treatment | Remarks | References |
|-------------|-----------|---------|------------|
| Cytokine release syndrome (CRS)/Cytokine storm: (a) cytokines are proteins that immune cells release when they attack an infection. The rapid and massive release of cytokines such as tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and interferon-γ (IFN-γ) into the bloodstream of patients can lead to fever, chills, hypotension, tachycardia, trouble breathing, and 1. Monitor vital signs, Ferritin levels, C-reactive protein (CRP) level. 2. Low-grade CRS management involves supportive care, including antipyretics, evaluation for alternative sources of fever, intravenous fluids for hydration, and antiemetics’ for nausea. 3. Higher-grade toxicities may require intravenous fluid boluses, support for hypotension, and high-flow oxygen for hypoxia. 4. The rapid destruction of engineered T cells depresses the CD19 CAR-T cells’ anti-tumor efficacy and [3,4,8,30,34] | | |
low oxygen. (b) CRS is considered an "on-target" effect of CAR-T cell therapy—as its presence shows that the T cells are in action, releasing the cytokines that stimulate the immune response against tumor cells.

Immune Effector Cell-associated Neurotoxicity Syndrome (ICANS): the diverse range of neurological toxicities include symptoms such as headache, dizziness, encephalopathy, confusion, delirium, decreased consciousness, language impairment (aphasia), brain edema, and seizures.

Tocilizumab (Actemra), an Interleukin -6 receptor antagonist (IL-6 is a major cytokine induced by CAR therapy), is used as a first-line treatment for CRS. Systemic corticosteroids are used for patients with life-threatening CRS.

On-target, Off-tumor Toxicity: CARS usually attack tumor-specific antigens. Sometimes, tumor-specific antigens are also expressed on healthy cells in essential tissues such as the heart, lung, or liver, which may be attacked by CAR-T cells, posing life-threatening risks.

Immunoglobulin replacement therapy may trigger subsequent disease progression or relapse.

Tocilizumab in mild cases and intravenous corticosteroids in severe cases [3,4,35]

B-Cell Aplasia: CAR-T cell therapy, which targets antigens present on the surface of B cells, destroys not only the cancerous B cells but also normal B cells (low numbers/ absence of B cells), leading to less availability of antibodies that protect against infection.

To prevent infections, Intravenous or subcutaneous immunoglobulin replacement therapy may be required.

While developing a CAR/TCR against an unrecognized target antigen on the tumor, its expression on normal tissues also needs to be examined.

[10]

Macrophage Activation Syndrome (MAS): in patients suffering from chronic autoimmune and rheumatic diseases, severe CRS is often associated with excessive multiplication of macrophages and T Cells.

Tocilizumab in mild cases and intravenous corticosteroids in severe cases [6]

Tumor Lysis Syndrome (TLS): after aggressive cancer treatment, the dead cancer cells enter the bloodstream and disrupt the blood chemical balance, leading to organ damage.

Splitting the initial dose of CAR-T Cells administration, monitoring of vital parameters along with the administration of corticosteroids.

[36]

Anaphylaxis: a life-threatening allergic reaction may occur in patients after repeated T cell infusion due to IgE antibody response against the scFv component of the CAR itself. Symptoms include facial swelling, low blood pressure, hives, and respiratory distress.

Proper monitoring and immediate treatment of this life-threatening side effect are essential for patients receiving CAR-T cell therapy.

[6]

Graft versus host disease (GVHD): GVHD is a cause of concern in patients who received prior hematopoietic stem cell transplantation (HSCT). It is triggered by the reactivity of donor-derived / allogeneic CAR T cells against recipient tissues.

Controlled by administering glucocorticoids and monoclonal antibodies.

[37]

**TABLE 2: Side-effects of CAR-T cell therapy and their treatments.**

| Side-effect | Treatment |
|-------------|-----------|
| CRS         | Tocilizumab (Actemra), an Interleukin -6 receptor antagonist (IL-6 is a major cytokine induced by CAR therapy), is used as a first-line treatment for CRS. Systemic corticosteroids are used for patients with life-threatening CRS. |
| ICANS       | Immunoglobulin replacement therapy may trigger subsequent disease progression or relapse. |
| On-target, Off-tumor Toxicity | Tocilizumab in mild cases and intravenous corticosteroids in severe cases [3,4,35] |
| B-Cell Aplasia | To prevent infections, Intravenous or subcutaneous immunoglobulin replacement therapy may be required. |
| MAS         | While developing a CAR/TCR against an unrecognized target antigen on the tumor, its expression on normal tissues also needs to be examined. |
| TLS         | Splitting the initial dose of CAR-T Cells administration, monitoring of vital parameters along with the administration of corticosteroids. |
| Anaphylaxis | Proper monitoring and immediate treatment of this life-threatening side effect are essential for patients receiving CAR-T cell therapy. |
| GVHD        | Controlled by administering glucocorticoids and monoclonal antibodies. |

**Factors That Affect the Potency of CAR-T Cell Activity**

2021 Rohit Reddy et al. Cureus 13(2): e13552. DOI 10.7759/cureus.13552
Other factors like immunogenicity (in case of repeated dosing, humanized scFvs should be used rather than mouse antibodies to prevent anaphylaxis or other severe dysfunctions), immunosuppressive components in the tumor microenvironment, immunosuppressive pretreatment prior to CAR-T infusion (causing anemia, coagulopathy, and neutropenic sepsis) may affect CAR-T cell activity and safety [10,32]. After the completion of treatment, the rate of cancer relapse is also a significant issue concerning CAR-T cell therapy's overall efficacy [18,36,39].

To overcome these limitations, researchers have developed some safety strategies to prevent or reduce the adverse effects of CAR-T cell therapies. The T cells so manufactured are called next-generation CAR-T cells [9,28,31,40].

**Next-Generation CAR-T Cells**

Researchers have been developing some safety strategies to prevent or reduce the adverse effects of CAR-T cell therapies. The T cells so manufactured are called next-generation CAR-T cells [9,28,31,40].

**Suicide gene switch:** It includes expressing a specific gene into the CAR T cells, which acts as a 'suicide gene switch' (activated by administering non-toxic molecules or associated monoclonal antibodies) to destroy the CAR T cells whenever there is a development of severe toxicity [9,31].

**Synthetic splitting receptor:** In synthetic splitting receptors proposed by Lim and colleagues, the timing, location, and dosage of T cell activity can be precisely and remotely controlled by pharmacologic regulation. In this system, the antigen binding and intracellular signaling components are separated in the absence of small molecules, and assembly starts after treatment with a heterodimerizing small molecule. Thus, the CAR-T cells can be effectively controlled with this small molecule in vivo, and the magnitude of responses such as target cell killing can be adjusted simply by changing the dosage of the small molecule. Another synthetic splitting receptor by Tulliber et al. is that the CAR architecture can be directly activated at the hinge domain with the addition of a small dimerizing molecule drug. The engineered CAR-T cell demonstrates a significant cell lysis activity after the use of the molecule inducer in a dose-dependent manner. The development of these novel controlled CAR-T cells opens innovative and attractive ways to control potentially adverse effects by improving the safety of CAR-T cell therapy in the clinic [9,28].

**Combinatorial target-antigen recognition:** It involves engineering the T Cells with two different CARs, which may be fully activated only after recognizing a set of different antigens expressed simultaneously on the tumor cells; e.g., the combination of CAR + Chimeric costimulatory receptor, Bispecific Tandem CAR. The normal cells that express only one of these antigens can't activate these T cells, thus significantly reducing on-target/off-tumor toxicity [9,28].

**Synthetic notch receptors:** The recent development of synthetic Notch (synNotch) receptors has helped avoid native T cells, thus overcoming toxicity in immunotherapy. SynNotch is composed of an extracellular antigen recognition domain (usually a single-chain variable fragment, scFv), a Notch core regulatory region, and an intracellular domain (ICD) [9,28,40]. SynNotch receptors use an extracellular domain to recognize a target antigen. However, as seen in CARs, binding of the target antigen does not trigger T cell activation. A synNotch receptor for one antigen drives the subsequent expression of a CAR targeting a second antigen. Only when both antigens are present, T cells can be activated. T cells with these receptors improve their effectiveness and safety profile [9,28].

**Bispecific T cell engager (BITE antibody composed of two single-chain antibodies):** Bispecific T cell engagers are built by connecting two scFvs through a linker (connector), which can simultaneously bind to two specific antibodies (scFvs) [9,28]. One of the scFvs binds to T cells via the CD3 receptor, and the other to a tumor cell via a tumor-specific antigen. In the absence of small bispecific molecules, these CAR-T cells are inactive against normal tissues. These cells improve T cells' potency and tumor selectivity, thereby enhancing their efficacy and safety [9,28]. A constructed monoclonal antibody, Blinatumomab, which targets CD19, was approved in 2014 for relapsed and refractory B cell ALL. They are safe and effective in improving long-term outcomes when used, along with tyrosine kinase inhibitors [31,41].

**Inhibitory chimeric antigen receptor:** The application of inhibitory receptors to CAR-T cells acts as a safety strategy. The Inhibitory chimeric antigen receptor (iCAR) consists of an scFv specific to the antigens expressed on normal tissue and a robust inhibitory signaling domain (from PD-1 and CTLA-4) to restrict T cell activity outside the tumor. The iCAR shows antigen-specific suppression of T cell activity, cytokine secretion, and proliferation in a temporary and reversible manner [9,28,40].

**Combination Therapies**

Researchers have tried the combination of CAR-T cell therapy with chemotherapy and radiotherapy to overcome the restrictions on usage of CAR-T cell therapy, reduce the adverse effects of the disease, enhance tumor antigen recognition, and increase the efficacy and persistence of CAR-T cells [2,41]. The combination of CAR-T cells and checkpoint inhibitor therapy (target PD-1 and PD-L1, CTLA-4, and B7 interactions) can also address the issue of antigen escape [42].
Other new areas of research in progress to improve the ability of CAR-T cells, resist the TME and decrease the immunogenicity include (1) multitargeted CAR-T cell technologies; (2) Reforms in the manufacture of T cells (e.g., decrease the risks associated with using virus vectors, including DNA damage, and reduce cost and time of production: by replacing them with nonvirus-based technologies, such as Sleeping Beauty and PiggyBac transposition leading to the production of T cells with high persistence and low DNA damage, thus solving the various potential insertion-related mutations); (3) gene-editing techniques including the use of a nonintegrated lentiviral vector, recruiting CAR-T cells by oncolytic virus equipped with chemokine genes, generation of CAR-T cells with CRISPR/cas9 technology (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein nine) and the use of CAR-NK (Natural killer) cells. Apart from the above-mentioned technical aspects, one more area that one needs to address to make CAR therapy more accessible is the huge cost involved. At present, in the USA, the price of Tiga-Cel (Kymriah) is $475,000, and that Axi-Cel (Yescarta) is $350,000, which may not be affordable to most people in the world, which is limiting the use of this therapy. We tabulated the various possible solutions to overcome the limitations of CAR-T therapy in order to aid in comprehension and a faster transition to application in the clinical field (Figure 4).

FIGURE 4: Summary of some of the strategies to overcome challenges in CAR-T cell therapy.

TRUCKs: T cells redirected for antigen unrestricted cytokine-initiated killing; CARs: chimeric antigen receptor

The success of ELIANA and ZUMA trials, resulting in FDA approval of several CAR-T cell therapies has led to progressive research related to the fourth generation and next-generation CAR-T cells, including the newest technologies, which are already under various phases of clinical trials around the world. The long-term benefits will be established only after substantial positive results on a large scale. Therefore, we finally infer that innovative bench research is required to strengthen the effectiveness of the advances in CAR-T cell therapy that will give physicians and patients the information and therapeutics to eliminate the malignancies. This review article’s limitations include a lack of statistical analysis among different studies in humans to compare individual effectiveness in various hematological cancers. Only studies over the past six years have been taken into consideration by the authors.

Conclusions

Globally, researchers are constantly on the lookout for novel strategies to combat cancer. CAR-T cell immunotherapy is one such area, which is under close observation to bring about a revolution in cancer cure. The anti-tumor functioning of CAR-T cells has inspired many during the last decade to carry out
various clinical trials and study the development, functions, and outcomes of CAR therapies. The FDA approval of some of the CAR treatments and their commercial viability heralded a new era in CAR Technologies. However, the limitations like unfavorable side effects, limited T cell persistence, tumor escape, immunosuppressive components in the tumor microenvironment (TME), rate of cancer relapse, and the huge cost of manufacturing involved are limiting the efforts of many to reap the full potential of CAR therapies. While the effectiveness of these inventions is being explored and established, it leaves a lot of scope and opportunities for future research to develop innovations in CAR technologies that can efficiently address the current limitations and lead to widespread adaptation of the treatment. The areas of interest for future researchers can be the optimization of CAR-T cell design, use of combined adoptive cell therapy/combination therapies, microenvironmental modification, and immune blockade strategies. Exploratory research to reduce relapse rates after achieving CR (complete remission) through multtargeted approaches or combination with other treatment methods is another critical area. More clinical studies may also be required to extend its application to cancers in other areas such as myeloid leukemia and solid cancers. In this review, we outlined the current status of CAR-T cell therapy growth, its applications in hematological malignancies, limitations, the latest developments in research to counter the challenges, and the future research scope to promote and extend its applications to existing and various other cancer treatments. Through this review, we intend to provide references for students, researchers, and colleagues in the field to better understand the present and future trends in CAR-T cell therapies.

Additional Information
Disclosures

Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References

1. Liu D: CAR-T ‘the living drugs,’ immune checkpoint inhibitors, and precision medicine: a new era of cancer therapy. J Hematol Oncol. 2019, 12:115. 10.1186/s13045-019-0819-1
2. Zhang Q, Ping J, Huang Z, et al.: CAR-T cell therapy in cancer: tribulations and road ahead. J Immunol Res. 2020, 2020:1924579. 10.1155/2020/1924579
3. Zhao Z, Chen Y, Francisco NM, Zhang Y, Wu M: The application of CAR-T cell therapy in hematological malignancies: advantages and challenges. Acta Pharm Sin B. 2018, 8:539-551. 10.1016/j.apsb.2018.05.001
4. CD19-Targeted CAR T cells as novel cancer immunotherapy for relapsed or refractory B-cell acute lymphoblastic leukemia. (2016). Accessed: December 22, 2020: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5556094/
5. Fujiwara H: Adoptive immunotherapy for hematological malignancies using T cells gene-modified to express tumor antigen-specific receptors. Pharmaceuticals. 2014, 7:1049-1068. 10.3390/ph71201049
6. Leukemia and lymphoma society chimeric antigen receptor (CAR) T-cell therapy. Accessed: December 10, 2020: https://www.lls.org/treatment/types-of-treatment/immunotherapy/chimeric-antigen-receptor-carr-t-cell-therapy.
7. June CH, Sadelain M: Chimeric antigen receptor therapy. N Engl J Med. 2018, 379:64-73. 10.1056/NEJMra1706169
8. Rutgers Cancer Institute of New Jersey. Advantages of CAR-T cell therapy. Accessed: December 15, 2020: https://www.cinj.org/patient-care/advantages-carr-cell-therapy.
9. Ren YB, Sun SJ, Han SY: Safety strategies of genetically engineered T cells in cancer immunotherapy. Curr Pharm Des. 2018, 24:78. 10.2174/138161282466171227222624
10. Almâshab H, Aarvak T, Vemuri MC: CAR T-cell therapy: a game changer in cancer treatment. J Immunol Res. 2016, 2016:5474602. 10.1155/2016/5474602
11. Nair R, Westin J: CAR T-cells. Adv Exp Med Biol. 2020, 1244:215-235. 10.1007/978-3-030-41008-7_10
12. Shank BR, Do B, Sevin A, Cher E, Neelapu SS, Horowitza SB: Chimeric antigen receptor T Cells in hematologic malignancies. Pharmacotherapy. 2017, 37:534-545. 10.1002/phar.1900
13. Bennmbearek MR, Karches CG, Cadilha BL, Lesch S, Endres S, Kohold S: Killing mechanisms of chimeric antigen receptor (CAR) T cells. Int J Mol Sci. 2019, 20:1283. 10.3390/ijms20061283
14. Rafiq S, Hackett CS, Brentjens RJ: Engineering strategies to overcome the current roadblocks in CAR T cell therapy. Nat Rev Clin Oncol. 2020, 17:147-167. 10.1038/s41571-019-0297-y
15. Boyiadzis MM, Dhodapkar MV, Brentjens RJ, et al.: Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance. J Immunother Cancer. 2018, 6:137. 10.1186/s40425-018-0460-x
16. Health & medication slideshows. CAR T-cell therapy: a healthcare professional’s guide – the top questions answered. (2020). Accessed: December 20, 2020: https://www.drugs.com/slideideshow/car-t-cell-therapy-top-10-questions-answered-1288.
17. Attrash S, Rano K, Harrison B, Abdallah AO: CAR-T treatment for hematological malignancies. J Investig Med. 2020, 68:956-964. 10.1156/jim-2020-001290
18. Song MK, Park BB, Ulm JE: Resistance mechanisms to CAR T-cell therapy and overcoming strategy in B-cell hematologic malignancies. Int J Mol Sci. 2019, 20:5010. 10.3390/ijms2005010
19. Zhao L, Cao YJ: Engineered T cell therapy for cancer in the clinic. Front Immunol. 2019, 10:2250. 10.3389/fimmu.2019.02250
20. FDA approval brings the first gene therapy to the United States. (2017). Accessed: December 20, 2020: https://www.fda.gov/news-events/press-announcements/fda-approval-brings-first-gene-therapy-united-states.

21. FDA news release FDA approves CAR-T cell therapy to treat adults with certain types of large B-cell lymphoma. (2017). Accessed: December 25, 2020: https://www.fda.gov/news-events/press-announcements/fda-approves-cara-t-cell-therapy-treat-adults-certain-types-large-

22. FDA news release FDA approves first cell-based gene therapy for adult patients with relapsed or refractory MCL. (2020). Accessed: December 25, 2020: https://www.fda.gov/news-events/press-announcements/fda-approves-first-cell-based-gene-therapy-adult-patients-relapse-

23. Grigor EJM, Ferguson D, Keke N, et al.: Risks and benefits of chimeric antigen receptor T-cell (CAR-T) therapy in cancer: a systematic review and meta-analysis. Transfus Med Rev. 2019, 33:98-110. 10.1016/j.tmrv.2019.01.005

24. Bonini C, Mondino A: Adoptive T-cell therapy for cancer: the era of engineered T cells. Eur J Immunol. 2015, 45:2457-2469. 10.1002/eji.201545552

25. Yañez L, Sánchez-Escamilla M, Perales MA: CAR T cell toxicity: current management and future directions. Hematop. 2019, 3:e186. 10.1097/HSP.000000000000186

26. Dotti G, Gottschalk S, Savoldo B, Brenner MK: Design and development of therapies using chimeric antigen receptor-expressing T cells. Immunol. Rev. 2014, 257:107-126. 10.1111/tmr.12151

27. Chmielewski M, Alikin H: TRUCKS, the fourth-generation CAR T cells: current developments and clinical translation. Adv Cell Gene Ther. 2020, 3:e84. 10.1002/acg2.84

28. Yu S, Yi M, Qin S, Wu K: Next-generation chimeric antigen receptor T cells: safety strategies to overcome toxicity. Mol Cancer. 2019, 18:125. 10.1186/s12943-019-1057-4

29. Wei J, Guo Y, Wang Y, et al.: Clinical development of CAR T cell therapy in China: 2020 update. Cell Mol Immunol. 2020, 10.1038/s41425-020-00555-z

30. Le RQ, Li L, Yuan W, et al.: FDA approval summary: tocilizumab for treatment of chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome. Oncolog. 2018, 25:945-947. 10.1634/theoncologist.2018-0028

31. Bonifant CL, Jackson HJ, Brentjens RJ, Curran KJ: Toxicity and management in CAR T-cell therapy. Mol Ther Oncol. 2016, 5:16011. 10.1058/mtot.2016.11

32. Beudno JN, Kochenderfer JN: Recent advances in CAR T-cell toxicity: mechanisms, manifestations, and management. Blood Rev. 2019, 34:45-55. 10.1016/j.bloodrev.2018.11.002

33. Chimeric antigen receptor T-cell therapy. (2020). Accessed: December 25, 2020: https://www.ncbi.nlm.nih.gov/books/NBK537294/.

34. Shimabukuro-Vornhagen A, Gödel P, Subklewe M, et al.: Cytokine release syndrome. J Immunother Cancer. 2018, 6:56. 10.1186/s40425-018-0345-9

35. Siegler EL, Kenderian SS: Neurotoxicity and cytokine release syndrome after chimeric antigen receptor T cell therapy: insights into mechanism and novel therapies. Front Immunol. 2020, 11:2057. 10.3389/fimmu.2019.2057

36. Sun S, Hao H, Yang G, Zhang Y, Fu Y: Immunotherapy with CAR-modified T Cells: toxicities and overcoming strategies. J Immunol Res. 2018, 2018:2386187. 10.1586/14710118.2018.2386187

37. Schroeder T, Haas R, Kolb G: Treatment of graft-versus-host disease with monoclonal antibodies and related fusion proteins. Expert Rev Hematol. 2010, 3:653-651. 10.1586/ehr.10.46

38. Ruella M, Xu J, Barrett DM, et al.: Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell. Nat Med. 2018, 24:1499-1505. 10.1038/s41591-018-0201-9

39. Cheng J, Zhao L, Zhang Y, et al.: Understanding the mechanisms of resistance to CAR T-cell therapy in malignancies. Front Oncol. 2019, 9:1237. 10.3389/fonc.2019.01237

40. Charrot S, Hallam S: CAR-T cells: future perspectives. Hematop. 2019, 3:e188. 10.1097/HSP.000000000000188

41. Zhao J, Song Y, Liu D: Recent advances on blinatumomab for acute lymphoblastic leukemia. Exp Hematol Oncol. 2019, 8:28. 10.1186/s40164-019-0152-y

42. Grosser R, Cherkansky L, Chintala N, Adusumilli PS: Combination immunotherapy with CAR T cells and checkpoint blockade for the treatment of solid tumors. Cancer Cell. 2019, 36:471-482. 10.1016/j.ccell.2019.09.006

43. Huang R, Li X, He Y, et al.: Recent advances in CAR-T cell engineering. J Hematol Oncol. 2020, 13:56. 10.1186/s13045-020-09910-5

44. Bachiller M, Battram AM, Perez-Amill L, Martín-Antonio B: Natural killer cells in immunotherapy: are we nearly there?. Cancers (Basel). 2020, 12:5159. 10.3390/cancers12115139

45. Tariq S, Haidar S, Hasan M, Tahir A, Khan M, Rehan A, Kamal A: Chimeric antigen receptor T-cell therapy: a beacon of hope in the fight against cancer. Cureus. 2018, 10:3486. 10.7759/cureus.3486

46. U.S. FDA approves kite’s tecartus™, the first and only CAR T treatment for relapsed or refractory mantle cell lymphoma. (2020). Accessed: December 30, 2020: https://www.gilead.com/news-and-press/press-room/press-releases/2020/7/us-fda-approves-kites-tecartus-the-first-and-a....